Navigation Links
Lotus Pharmaceuticals Announces Two Senior Management Appointments
Date:9/23/2010

Lotus Pharmaceuticals Announces Two Senior Management Appointments -- BEIJING, Sept. 23 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Lotus Pharmaceuticals Announces Two Senior Management Appointments

 

BEIJING, Sept. 23 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company has appointed Mr. Xing Shen as its Vice President of Corporate Development and Ms. Yan Zeng as its Chief Financial Officer. Ms. Zeng, who served as CFO of Lotus in 2009 and early 2010, will relieve Mr. Jeff Hon. Mr. Hon submitted his resignation to the Company's board of directors, effective September 22, citing personal reasons.

In his new role as Vice President of Corporate Development, Mr. Xing Shen will oversee the Company's strategic business development and internal investor relations functions. Prior to his tenure with Lotus, Mr. Shen worked as an equity analyst at RBC Capital Markets, covering companies in the biotech space. He holds an MBA and a PhD in molecular cancer biology, both from Duke University, as well as a Master of Science degree from Peking University and a Bachelor of Science degree from Wuhan University.

Ms. Yan Zeng is a certified public accountant (CPA) and served as the Company's Chief Financial Officer prior to Jeff Hon's appointment. She also has accounting experience with Liang Fang Pharmaceutical Ltd., a subsidiary of the Company. Prior to joining the Company, Ms. Zeng worked as a registered accountant and auditor with Beijing Topson Certified Public Accountants and as a financial manager for Beijing Unite Youbang Science and Technology Ltd. She holds a bachelor's degree in business from Beijing Information Science and Technology University.

"We are pleased to have Dr. Shen serve as our VP of Corporate Development and believe that his experience with the Company and background in both biotech and finance will prove to be a powerful combination that will benefit Lotus over the long run. We are also pleased to have Yan Zeng return as our CFO, despite Jeff Hon's unfortunate departure," said Dr. Zhongyi Liu, Lotus' Chairman and Chief Executive Officer. "By building a solid senior management team with significant industry experience, we are positioning ourselves to capture a greater share of the pharmaceutical market in China and sustain a high rate of growth while maintaining internal control."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.

For more information, please contact: At the Company: Xing Shen, Ph.D. VP of Corporate Development Lotus Pharmaceuticals, Inc. Tel: +1-415-200-8482 Email: shen@lotuspharma.com Web: http://www.lotuspharma.com Investor Relations: Dave Gentry RedChip Companies, Inc. Tel: +1-800-733-2447 x104 Email: info@redchip.com Web: http://www.RedChip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
2. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
3. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
4. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
5. Lotus Pharmaceuticals Terminates SEDA
6. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
7. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
8. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
9. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
10. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
11. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):